Sunday, May 25, 2025

Roche Expands AI Cancer Diagnostics with Digital Pathology

Related stories

Neural Networks vs Deep Learning: Key Differences Explained

In the fast-paced world of AI, two key terms...

Diligent Acquires Vault to Advance AI Ethics & Compliance

Acquisition Brings Vault’s Best in AI-driven Automation, Ethical Risk...

Stargate UAE Launched by Global Tech Alliance

In a groundbreaking move signaling a new era of...

Pigment & Google Cloud Team Up on AI Business Planning

Partnership powers Pigment's growth, utilizing Google Cloud's AI infrastructure...
spot_imgspot_img

Roche announced the expansion of its digital pathology open environment with the integration of more than 20 advanced artificial intelligence (AI) algorithms from eight new collaborators. These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by leveraging cutting-edge AI technology.

The seamless integration is facilitated through Roche’s navify® Digital Pathology enterprise software, an application for the pathologist’s workflow, which now incorporates a diverse range of AI-driven algorithms, creating easy access to third-party innovation. These AI tools are designed to enhance pathology insights, helping benefit cancer patients through precision medicine and enabling targeted treatments.

“We are excited to welcome these new collaborators into our digital pathology ecosystem,” said Jill German, Head of Pathology Lab for Roche Diagnostics. “By combining our leadership in tissue diagnostics with a broad offering of state-of-the-art AI technology, we aim to revolutionise cancer research, diagnostics and treatment, ultimately helping clinicians improve the lives of patients worldwide.”

Also Read: Carterra Ultra™: New Era in Biosensor Drug Discovery

The collaborators are:

  • Deep Bio: Algorithm for prostate cancer detection, grading, and tumour quantification
  • DiaDeep: Algorithms for breast cancer biomarker quantification
  • Lunit: Tumour proportion score (TPS) analysis for non-small cell lung cancer
  • Mindpeak: Algorithms for breast biomarkers and pan tumour PD-L1 for lung, gastric, esophageal, bladder and breast cancers
  • Owkin: Algorithm for the screening of microsatellite stability in colorectal cancer
  • Qritive: Algorithms for screening and grading of prostate cancer, analysing lymph nodes for metastasis, and screening for colon cancer
  • Sonrai Analytics: Algorithm for determining microsatellite instability (MSI) status in colorectal cancer
  • Stratipath: Algorithm for risk profiling of invasive breast cancer

With these new collaborations and integrations, Roche emphasises its commitment to improving patient outcomes and advancing personalised healthcare by providing scientists and clinicians with the resources they need to deliver precise and effective cancer diagnoses.

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img